Holen Sie sich die Stockscreener-App
0.97
2.11%
0.02
Handel nachbörslich:
.97
Schlusskurs vom Vortag:
$0.95
Offen:
$0.93
24-Stunden-Volumen:
43,554
Relative Volume:
0.47
Marktkapitalisierung:
$27.17M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-61.28M
KGV:
-0.3849
EPS:
-2.52
Netto-Cashflow:
$-46.46M
1W Leistung:
-10.19%
1M Leistung:
-25.38%
6M Leistung:
-35.33%
1J Leistung:
-14.91%
1-Tages-Spanne:
$0.93
$0.9885
1-Wochen-Bereich:
$0.8702
$1.07
52-Wochen-Spanne:
$0.8702
$2.57
Nextcure Inc Stock (NXTC) Company Profile
Firmenname
Nextcure Inc
Sektor
Branche
Telefon
240-399-4900
Adresse
9000 VIRGINIA MANOR ROAD, SUITE 200, BELTSVILLE, MD
Vergleichen Sie NXTC mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NXTC
Nextcure Inc
|
0.97 | 27.17M | 0 | -61.28M | -46.46M | -2.19 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Nextcure Inc Stock (NXTC) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2022-11-04 | Herabstufung | Ladenburg Thalmann | Buy → Neutral |
| 2022-03-01 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2021-03-05 | Hochstufung | Truist | Hold → Buy |
| 2021-01-15 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2020-07-16 | Hochstufung | The Benchmark Company | Hold → Buy |
| 2020-07-13 | Herabstufung | ROTH Capital | Buy → Neutral |
| 2020-07-13 | Herabstufung | SunTrust | Buy → Hold |
| 2020-06-01 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2020-06-01 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2020-05-26 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2020-03-24 | Eingeleitet | The Benchmark Company | Buy |
| 2020-03-02 | Eingeleitet | ROTH Capital | Buy |
| 2020-01-13 | Eingeleitet | SunTrust | Buy |
| 2019-12-05 | Eingeleitet | Needham | Buy |
| 2019-11-26 | Eingeleitet | BTIG Research | Buy |
| 2019-07-09 | Eingeleitet | BofA/Merrill | Buy |
| 2019-06-03 | Eingeleitet | Morgan Stanley | Overweight |
| 2019-06-03 | Eingeleitet | Piper Jaffray | Overweight |
Alle ansehen
Nextcure Inc Aktie (NXTC) Neueste Nachrichten
NextCure stock hits 52-week low at $0.99 amid market challenges By Investing.com - Investing.com South Africa
NextCure stock hits 52-week low at $0.99 amid market challenges - Investing.com India
FDA clears IND for B7-H4-targeting ADC - BioWorld Online
NextCure Announces Acceptance of IND Application for LNCB74 - The Manila Times
NextCure, Inc. Announces Acceptance of IND Application for LNCB74 - Marketscreener.com
NextCure stock hits 52-week low at $1.00 amid market challenges - Investing.com Australia
NextCure stock hits 52-week low at $1.00 amid market challenges By Investing.com - Investing.com South Africa
NextCure Advances with New Cancer Drug Application - TipRanks
NextCure to Participate in the 36th Annual Piper Sandler Healthcare Conference - The Manila Times
Preclinical Data Demonstrates Anti-Siglec-15 Treatment Enhanced Generation of Quality Bone with Better Mechanical Properties in Mice with Moderate-to-Severe Osteogenesis Imperfecta - The Manila Times
NextCure's NC605 Shows 90% Fracture Prevention in Breakthrough Bone Disease Study | NXTC Stock News - StockTitan
Logos Global Management LP Reduces Stake in NextCure Inc - GuruFocus.com
Affinity Asset Advisors, LLC Increases Stake in NextCure Inc - GuruFocus.com
Here's Why We're Watching NextCure's (NASDAQ:NXTC) Cash Burn Situation - Simply Wall St
NextCure Reports Improved Financial Performance and Strategic Focus - TipRanks
National Presto Industries, Inc. (NYSE:NPK) Shares Sold by State of Alaska Department of Revenue - Defense World
NextCure Provides Business Update and Reports Third Quarter 2024 Financial Results - The Manila Times
NextCure Reports Preclinical Data for LNCB74 and Additional Clinical Biomarker Data for NC410 Combo at Society for Immunotherapy of Cancer Annual Meeting - The Manila Times
NextCure Reports Preclinical Data for LNCB74 and Additional Clin - WICZ
NextCure (NASDAQ:NXTC) Shares Down 3.6% – Here’s Why - Defense World
Intuitive Surg Inc (ISRG-Q) QuotePress Release - The Globe and Mail
NextCure to Give Two Presentations at Society for Immunotherapy of Cancer Annual Meeting - The Manila Times
Elevation Capital Advisory LLC Purchases New Shares in Vanguard Information Technology ETF (NYSEARCA:VGT) - americanbankingnews.com
Affinity Asset Advisors LLC Invests $432,000 in NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO) - Defense World
NextCure, Inc. (NASDAQ:NXTC) Shares Purchased by Logos Global Management LP - Defense World
Next plc Executes Share Buyback Program - TipRanks
Nexteq PLC Announces Share Buyback and Voting Rights Update - TipRanks
Next PLC Executes Share Buy-Back for Cancellation - TipRanks
Next plc Conducts Share Buyback and Cancellation - TipRanks
Next lifts profit guidance to almost £1bn - Investors Chronicle
Next PLC’s Fresh Guidance Lift, Overseas Plans Boost Shares - The Wall Street Journal
Next PLC Impresses Investors with Yet Another Guidance Upgrade - TipRanks
Next is approaching a historic profit landmark- what is driving this growth? - Proactive Investors Australia
Next Shares Rise 3% As Full-Year Estimates Hiked - Forbes
Next shares rise on upbeat full-year profit outlook By Investing.com - Investing.com South Africa
Record high for Next shares after guidance raised again - Interactive Investor
Next Lifts Profit Target Again as Autumn Fashion Sales Surge - BNN Bloomberg
UK's Next raises forecast to put 1 billion pound profit in sight - Reuters
Britain's Next on track for 1 billion pounds annual profit - Marketscreener.com
Next Raises FY Pre-Tax Profit Guidance By £15 Mln - XM
NextCure Presented Results of the Phase 1b Study of NC410 in Combination with Pembrolizumab at ESMO 2024 - ForexTV.com
Is NextCure (NASDAQ:NXTC) In A Good Position To Deliver On Growth Plans? - Yahoo Finance
Assenagon Asset Management S.A. Sells 864 Shares of Stantec Inc. (NYSE:STN) - Defense World
Assenagon Asset Management S.A. Buys 131 Shares of Watsco, Inc. (NYSE:WSO) - Defense World
Assenagon Asset Management S.A. Sells 473,491 Shares of U.S. Silica Holdings, Inc. (NYSE:SLCA) - Defense World
Vanguard Group Inc. Raises Stock Holdings in NextCure, Inc. (NASDAQ:NXTC) - Defense World
NextCure (NASDAQ:NXTC) Stock Rating Reaffirmed by Needham & Company LLC - Defense World
NextCure, Inc. (NASDAQ:NXTC) Sees Significant Drop in Short Interest - Defense World
NextCure (NASDAQ:NXTC) Trading Down 3.6% - Defense World
We're Keeping An Eye On NextCure's (NASDAQ:NXTC) Cash Burn Rate - Simply Wall St
Advanced Gastric Carcinoma Pipeline 2024 | Jiangsu Hengrui - openPR
Finanzdaten der Nextcure Inc-Aktie (NXTC)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.88%
2.65%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):